Forest Arnold, DO
Infectious Disease · Louisville, KYNPI 1134119472
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,309 of the $3,909 with a category attached, or 84.7%. It is spread thinly across 16 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations.
Across 202 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$867
- Gilead$616
- Merck$451
- Pfizer$439
- AbbVie$431
- Insmed, Inc.$321
- plus $783 from 10 others
Across 145 payments — averaging $28,154 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3M
- Janssen Research & Development, LLC$595K
- Johnson & Johnson$302K
- Merck$127K
- Roche TCRC, Inc.$67K
- Astrazeneca UK Limited$17K
- plus $21K from 2 others
What the payments were for
- Food & beverage$3,30985%
- Education$60015%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 31 | $867 |
| Gilead | 36 | $616 |
| Merck | 27 | $451 |
| Pfizer | 27 | $439 |
| AbbVie(2 entities) | 25 | $431 |
| Insmed, Inc. | 12 | $321 |
| Shionogi Inc | 8 | $199 |
| Melinta Therapeutics, LLC | 11 | $185 |
| Viiv Healthcare Company | 7 | $118 |
| Paratek Pharmaceuticals, Inc. | 5 | $71 |
| Ferring Pharmaceuticals Inc. | 3 | $55 |
| Tetraphase Pharmaceuticals, Inc. | 4 | $52 |
| Johnson & Johnson | 3 | $42 |
| Novavax Inc | 1 | $23 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Oxford Immunotec USA Inc | 1 | $15 |
How this compares
$3,909 in reported general payments places this provider in the 75th percentile of 100 infectious disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 116 | $434,365 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 39 | $164,848 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 44 | $157,648 |
| TivicayDolutegravir Sodium | 55 | $113,451 |
| DescovyEmtricitabine/Tenofov Alafenam | 30 | $61,752 |
| PrezcobixDarunavir/Cobicistat | 25 | $57,872 |
| PifeltroDoravirine | 12 | $18,686 |
| EvotazAtazanavir Sulfate/Cobicistat | 11 | $15,743 |
| Maraviroc | 12 | $9,100 |
| Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl | 89 | $6,915 |
| TwinrixHepatitis A And B Vaccine/Pf | 15 | $2,385 |
| Atazanavir Sulfate | 12 | $2,148 |
| Typhim ViTyphoid Vi Polysacch Vaccine | 15 | $1,811 |
| Efavirenz | 12 | $1,210 |
| Azithromycin | 191 | $818 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $616 | $496,117146 claims |
| Viiv Healthcare CompanyTriumeq, Tivicay | $118 | $271,09999 claims |
| Johnson & JohnsonPrezcobix | $42 | $57,87225 claims |
| MerckPifeltro | $451 | $18,68612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 100 infectious disease providers in Kentucky.
Other infectious disease in Louisville
- Julio RamirezLouisville$256K
- Martin GnoniLouisville$194K
- Paul SchulzLouisville$189K
- Tariq MehmoodLouisville$75K
- Anupama RaghuramLouisville$9K
- Barbara WojdaLouisville$7K
- Benjamin KlausingLouisville$7K
- Kamran AkhtarLouisville$4K
- Mark BurnsLouisville$3K
- Kenechukwu ObiokoyeLouisville$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.